DOCK10 Regulates Insulin Hypersecretion in Insulinoma and Serves as a Diagnostic and Therapeutic Target

Hiromune Katsuda1, Go Ito2, Franziska Kimmig3

  • 1Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.

Abstract

Insights

Researchers identified dedicator of cytokinesis 10 (DOCK10) as a key regulator of insulin secretion in insulinomas. Targeting the DOCK10-Cdc42 pathway may offer new diagnostic and therapeutic strategies for these rare pancreatic tumors.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Insulinomas, rare pancreatic neuroendocrine neoplasms (pan-NENs), cause inappropriate insulin secretion, posing diagnostic and therapeutic challenges.
  • Current diagnostic tools and treatments for insulinomas are limited, indicating a critical need for novel approaches.

Purpose of the Study:

  • To elucidate the molecular mechanisms driving insulin hypersecretion in insulinomas.
  • To identify potential diagnostic markers and therapeutic targets for insulinoma.

Main Methods:

  • Established a biobank of human insulinoma specimens and organoids.
  • Conducted comprehensive transcriptomic analyses (bulk RNA-seq, scRNA-seq, qPCR, IHC).
  • Performed functional validation using cell lines, xenograft models, and patient-derived organoids.

Main Results:

  • Identified dedicator of cytokinesis 10 (DOCK10) as significantly overexpressed in insulin-secreting insulinoma components.
  • DOCK10 knockdown reduced glucose-stimulated insulin secretion in mouse cells and human organoids.
  • Inhibition of the DOCK10-Cdc42 pathway with ML141 decreased insulin hypersecretion and improved survival in a mouse model.

Conclusions:

  • The DOCK10-Cdc42 axis plays a crucial role in regulating insulin secretion in insulinoma.
  • DOCK10 shows potential as a diagnostic marker for insulin-secreting lesions.
  • DOCK10 represents a promising therapeutic target for insulinoma treatment.

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.1K